miRNA-124 as a biomarker
AssigneesAbivax, Centre National de la Recherche, Universite De Montpellier, Institut Curie
InventorsJamal Tazi, Didier Scherrer, Aude Garcel, Noëlie Campos, Romain Najman, Florence Mahuteau-Betzer
Life of this patent
Estimating the term…
Abstract
A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.
Claims14
An in vitro or ex vivo method of measuring miR-124 in a patient with a HIV infection, comprising at least the steps of:
- a. obtaining a biological sample from said patient, said biological sample selected from the group consisting of:
- a whole blood sample, a swab sample, a plasma sample, a serum sample, a saliva sample, a vaginal fluid sample, a sperm sample, a pharyngeal fluid sample, a bronchial fluid sample, a fecal fluid sample, and a lacrymal fluid sample;
- and
- b. measuring a presence or expression level of at least miR-124 in the biological sample from said patient,
- wherein measuring the presence or expression level of miR-124 comprises contacting the biological sample with a nucleic acid probe able to specifically hybridize to miR-124, and detecting the hybridization of said probe to miR-124,
- wherein said nucleic acid probe includes a nucleic acid sequence selected from the group consisting of SEQ ID NOS:
- 6 to 86.
An in vitro or ex vivo method of assessing an activity of a quinoline derivative of formula (I) or (II) or one of their pharmaceutically acceptable salts, for preventing and/or treating a HIV infection in a patient treated with said quinoline derivative, comprising at least the steps of:
- a. measuring a presence or an expression level of at least one miRNA, including miR-124, in a first biological sample previously obtained from said patient before administering said quinoline derivative and in a second biological sample previously obtained from said patient after administering said quinoline derivative;
- and
- b. determining if said presence or expression level is modulated in the second biological sample obtained after the treatment as compared to the first biological sample obtained before the treatment;
- wherein a modulated presence or expression level of said miRNA is indicative of an activity of said quinoline derivative;
- wherein formula (I) is:
- where:
- n is 1 or 2;
- R independently represents:
- a hydrogen atom,
- a halogen atom,
- a (C1-C3) alkyl group,
- a —NR1R2 group in which R1 and R2 are independently a hydrogen atom or a (C1-C3) alkyl group,
- a (C1-C3) fluoroalkoxy group,
- a —NO2 group,
- a phenoxy group, or
- a (C1-C4) alkoxy group;
- R′ is a hydrogen atom, a halogen atom, a (C1-C4) alkyl group, or a (C1-C4) alkoxy group;
- and
- R″ is a hydrogen atom or a (C1-C4) alkyl group;
- and
- wherein formula (II) is:
- where:
- n is 1 or 2;
- R independently represents:
- a hydrogen atom,
- a halogen atom,
- a (C1-C3) alkyl group,
- a —CN group,
- a hydroxyl group,
- a —COOR1 group,
- a (C1-C3) fluoroalkyl group,
- a —NO2 group,
- a —NR1R2 group, or
- a (C1-C4) alkoxy group;
- R1 and R2 are independently a hydrogen atom or a (C1-C3) alkyl group;
- R′ is a hydrogen atom, a halogen atom, a (C1-C4) alkyl group, or a (C1-C4) alkoxy group;
- and
- R″ is a hydrogen atom or a (C1-C4) alkyl group.
An in vitro or ex vivo method for measuring miRNA expressed by one or more cells treated with a candidate compound presumed effective in preventing and/or treating a HIV infection, comprising at least the steps of:
- a. treating at least one isolated cell able to express at least one miRNA, the at least one miRNA being miR-124, with said candidate compound, said cell being under conditions suitable for expressing said at least one miRNA;
- and
- b. measuring a presence or expression level of said at least one miRNA;
- wherein said candidate compound is a quinoline derivative represented by formula (I) or one of its pharmaceutically acceptable salts:
- where:
- n is 1 or 2;
- R independently represents:
- a hydrogen atom,
- a halogen atom,
- a (C1-C3) alkyl group,
- a —NR1R2 group in which R1 and R2 are independently a hydrogen atom or a (C1-C3) alkyl group,
- a (C1-C3) fluoroalkoxy group,
- a —NO2 group,
- a phenoxy group, or
- a (C1-C4) alkoxy group;
- R′ is a hydrogen atom, a halogen atom, a (C1-C4) alkyl group, or a (C1-C4) alkoxy group;
- and
- R″ is a hydrogen atom or a (C1-C4) alkyl group;
- or wherein said candidate compound is a quinoline derivative represented by formula (II) or one of its pharmaceutically acceptable salts:
- where:
- n is 1 or 2;
- R independently represents:
- a hydrogen atom,
- a halogen atom,
- a (C1-C3) alkyl group,
- a —CN group,
- a hydroxyl group,
- a —COOR1 group,
- a (C1-C3) fluoroalkyl group,
- a —NO2 group,
- a —NR1R2 group, or
- a (C1-C4) alkoxy group;
- R1 and R2 are independently a hydrogen atom or a (C1-C3) alkyl group;
- R′ is a hydrogen atom, a halogen atom, a (C1-C4) alkyl group, or a (C1-C4) alkoxy group;
- and
- R″ is a hydrogen atom or a (C1-C4) alkyl group.
An in vitro or ex vivo method for measuring miRNA expressed by one or more cells treated with a candidate compound presumed effective in treating a HIV infection, comprising at least the steps of:
- a. treating at least one isolated cell able to express at least one miRNA, the at least one miRNA being miR-124, with said candidate compound, said cell being under conditions suitable for expressing said at least one miRNA;
- and
- b. measuring a presence or expression level of said at least one miRNA.
Dependencies are inferred from the claim text.